Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility
Gastroparesis · Dyspepsia
Primary: Frequency of Contractions at Baseline — 20; 24.6; 23.7 stomach contractions/minute
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
Phase 2 N=57 A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastroparesis
Primary: Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline — 24.13; 24.81…
N/A N=24 Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers
Gastroparesis
Primary: Gastroduodenal Manometry Measurement — 9.862; 10.38; 10.38; 8.433 motility index units (see Description)
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
N/A N=22 Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis
Gastric Stasis
Primary: Percentage of Slow Wave Entrainment — 72; 70; 84; 78 percentage of slow waves entrainment
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
N/A N=32 Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
Gastroparesis
Primary: Symptom Response as Assessed by the Gastroparesis Cardinal Symptom Index. — 6.8; 10.1 units on a scale
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
Phase 3 N=130 Nortriptyline for Idiopathic Gastroparesis
Idiopathic Gastroparesis
Primary: Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits — 15; 14 participants — p=0.86
Phase 2 N=25 Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Gastroparesis
Primary: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate — 267.12; 283.09; 221.74 kPCD/minutes — p=<0.05
N/A N=48 Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
Phase 2 N=96 Buspirone for Early Satiety and Symptoms of Gastroparesis
Gastroparesis
Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69
N/A N=9 Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Gastroparesis
Primary: Gastric Accommodation — 322.22; 402.78; 450.63 ml
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
N/A N=88 Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
Gastrointestinal Diseases
Primary: Device Success Defined as the Ability to Record Myoelectric Signals in Study Subjects. — 88 participants
Phase 2 N=104 Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
Phase 2 N=110 Metoclopramide Versus Placebo for GJ Placement
Radiation Exposure · Enteral Nutrition
Primary: Time to Duodenal Intubation — 1.6; 4.1 Minutes
N/A N=10 Erythromycin in Parkinson's Disease
Parkinson's Disease · Levodopa
Primary: Gastric Emptying Time — 105; 180 minutes — p=0.036
Phase 4 N=22 Effect of Dexmedetomidine of Gastrointestinal Motility
Anesthesia
Primary: Intra-anal Sphincter Pressure (IASP) 1 Minute After Dexmedetomidine Administration — 62.9 mmHg
Phase 2 N=36 Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids — 3.5; -19.8; -25.4; -25.7 percent change — p=0.0012
Early Phase 1 N=14 Pioglitazone for Idiopathic Gastroparesis
Gastroparesis
Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…
Phase 3 N=40 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Healthy
Primary: Gastric Volume — 262; 718 mL — p=<0.0001
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Phase 2 N=12 Lanreotide in the Treatment of Small Bowel Motility Disorders
Gastrointestinal Motility Disorder · Intestinal Disease
Primary: Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill — 371.52; 392; 4767; 5159 minutes — p=0.07
Phase 2 N=92 Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Gastroparesis · Dyspepsia
Primary: Gastric Emptying Half-time (T1/2) of Solids — 128.7; 125.8; 246.4; 198.4 minutes
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
Phase 4 N=13 Effect of Octreotide on the Colonic Motility in Pediatric Patients
Colonic Motility Index · Constipation
Primary: Compared Colonic Motility Index From Fasting to Post Octreotide Infusion — 6.03; 6.89; 7.73; 5.32 mm Hg — p=0.087